These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 4072846)

  • 1. [A population study of the poor metabolizers of the debrisoquine type in Japan].
    Hayashi M; Takase M
    Nippon Ganka Gakkai Zasshi; 1985 Aug; 89(8):983-90. PubMed ID: 4072846
    [No Abstract]   [Full Text] [Related]  

  • 2. The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol.
    Lennard MS; Jackson PR; Freestone S; Tucker GT; Ramsay LE; Woods HF
    Br J Clin Pharmacol; 1984 Jun; 17(6):679-85. PubMed ID: 6743465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population study of poor debrisoquine-type metabolizers of propranolol among Japanese.
    Hayashi M; Takase M
    Jpn J Ophthalmol; 1985; 29(3):272-81. PubMed ID: 4079124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymorphism of debrisoquine 4-hydroxylation and family studies of poor metabolizers in Chinese population.
    Du YL; Lou YQ
    Zhongguo Yao Li Xue Bao; 1990 Jan; 11(1):7-10. PubMed ID: 2403020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Debrisoquine polymorphism and the metabolism and action of metoprolol, timolol, propranolol and atenolol.
    Lennard MS; Tucker GT; Silas JH; Woods HF
    Xenobiotica; 1986 May; 16(5):435-47. PubMed ID: 2874665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The oral clearance and beta-adrenoceptor antagonist activity of propranolol after single dose are not related to debrisoquine oxidation phenotype.
    Lennard MS; Jackson PR; Freestone S; Ramsay LE; Tucker GT; Woods HF
    Br J Clin Pharmacol; 1984; 17 Suppl 1(Suppl 1):106S-107S. PubMed ID: 6146334
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacokinetics and beta-blocking effects of timolol in poor and extensive metabolizers of debrisoquin.
    McGourty JC; Silas JH; Fleming JJ; McBurney A; Ward JW
    Clin Pharmacol Ther; 1985 Oct; 38(4):409-13. PubMed ID: 2864157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Timolol metabolism and debrisoquine oxidation polymorphism: a population study.
    Lennard MS; Lewis RV; Brawn LA; Tucker GT; Ramsay LE; Jackson PR; Woods HF
    Br J Clin Pharmacol; 1989 Apr; 27(4):429-34. PubMed ID: 2719899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment.
    Brøsen K; Gram LF; Haghfelt T; Bertilsson L
    Pharmacol Toxicol; 1987 Apr; 60(4):312-4. PubMed ID: 3588528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxidation phenotyping in Chinese and Malay populations.
    Lee EJ; Nam YP; Hee GN
    Clin Exp Pharmacol Physiol; 1988 Nov; 15(11):889-91. PubMed ID: 3229012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic absorption of ocular timolol in poor and extensive metabolizers of debrisoquine.
    Huupponen R; Kaila T; Lahdes K; Salminen L; Iisalo E
    J Ocul Pharmacol; 1991; 7(2):183-7. PubMed ID: 1919275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Debrisoquine oxidation in a Finnish population: the effect of oral contraceptives on the metabolic ratio.
    Kallio J; Lindberg R; Huupponen R; Iisalo E
    Br J Clin Pharmacol; 1988 Dec; 26(6):791-5. PubMed ID: 3242585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymorphism of the 4-hydroxylation of debrisoquine in the San Bushmen of southern Africa.
    Sommers DK; Moncrieff J; Avenant J
    Hum Toxicol; 1988 May; 7(3):273-6. PubMed ID: 3391625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low frequency of slow debrisoquine hydroxylation in a native Chinese population.
    Lou YC; Ying L; Bertilsson L; Sjöqvist F
    Lancet; 1987 Oct; 2(8563):852-3. PubMed ID: 2889047
    [No Abstract]   [Full Text] [Related]  

  • 15. The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.
    Lennard MS; Tucker GT; Woods HF
    Clin Pharmacokinet; 1986; 11(1):1-17. PubMed ID: 2868819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ethnic difference in drug metabolism: debrisoquine 4-hydroxylation in Caucasians and Orientals.
    Kalow W; Otton SV; Kadar D; Endrenyi L; Inaba T
    Can J Physiol Pharmacol; 1980 Sep; 58(9):1142-4. PubMed ID: 7459706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-correlation between debrisoquine and metoprolol polymorphisms in the Venda.
    Sommers DK; Moncrieff J; Avenant J
    Hum Toxicol; 1989 Sep; 8(5):365-8. PubMed ID: 2807305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of cimetidine on debrisoquine 4-hydroxylation in extensive metabolizers.
    Philip PA; James CA; Rogers HJ
    Eur J Clin Pharmacol; 1989; 36(3):319-21. PubMed ID: 2744073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine.
    Bertilsson L; Dengler HJ; Eichelbaum M; Schulz HU
    Eur J Clin Pharmacol; 1980 Feb; 17(2):153-5. PubMed ID: 7371707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enantioselectivity of 4-hydroxylation in extensive and poor metabolizers of debrisoquine.
    Eichelbaum M; Bertilsson L; Küpfer A; Steiner E; Meese CO
    Br J Clin Pharmacol; 1988 Apr; 25(4):505-8. PubMed ID: 3382592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.